Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

The Federal Reserve's widely panned and soon-to-be-revised "average inflation targeting" strategy may survive mostly intact ...

Research shows that promoting fruits and vegetables isn't enough to combat weight gain, highlighting the significant role of ...

Even though the Fed has mostly muffled the idea since - as multiple shocks saw inflation explode briefly in the interim - the ...